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Abstract 
Accumulating evidence supports the hypothesis that beta-amyloid (PA) plays a role in the 
degeneration of cholinergic neurons in the basal forebrain. Degeneration of the basal forebrain 
cholinergic system, which is implicated in learning and memory function, is a characteristic of 
Alzheimer's disease. It has been previously reported that injections of PA(25-35) into the medial septal 
area (MSA) of rats produce a hypofunction of the cholinergic system and a decrease in ACh release in 
the hippocampus. Investigators report mixed results in the development of behavioral spatialleaming 
impairments following single injections of pA. Recent studies suggest that multiple injections or 
chronic administration of pA results in more consistent spatial learning impairments. One such study 
recently presented at a neuroscience symposium in Chicago further suggests behavioral deficits in 
spatialleaming ability as a result of a more extensive lesion following the administration of multiple 
injections of PA(25-35) into the medial septal area. This study replicates and extends this experiment. 
Injections of 5nm of PA(25-35) were administered into three different levels of the MSA in the male 
rat and following these injections their spatial learning ability was tested on the Morris water maze and 
radial arm maze. No significant spatial learning deficits were noted in animals receiving injections of 
PA(25-35) when compared to controls. 
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The Effects of Multiple Injections of PA(25-35) into the Medial Septal Area 
On Spatial Learning in the Male Rat 
Millions ofpeople are currently afflicted with Alzheimer's disease, which is a 
neurodegenerative disease ofaging characterized by a progressive loss of memory. Some of the 
neuropathological hallmarks of Alzheimer's disease are neuronal death within the basal forebrain 
accompanied by the appearance of neurofibrillary tangles and neuritic plaques. The major component 
of neuritic plaques found in the brains of Alzheimer's patients has been identified as a peptide known 
as beta-amyloid (pA)(for review see Robakis, 1994). One hypothesis of the etiology of Alzheimer's 
disease (AD) is that aggregation of pA into neuritic plaques leads to selective cell death, resulting in 
the formation of the behavioral deficits found in AD. Indeed, investigation of the properties and role of 
pA has provided support for a causal role of pA in the neurodegeneration characteristic in the 
development of AD (for review see Cotman & Pike, 
1994). 
Inyi\To toxicity of two different pA fragments, pA (1-40) and pA (25-35), has been found 
following injections into the cerebral cortex of rats and monkeys, resulting in lesions larger than 
those caused by control peptides (Kowall, McKee, Yanker, & Beal, 1992). In aged primate cortex pA 
(1-40) lesion size has been found to be dose-dependent, suggesting that pA fragments are acutely 
neurotoxic (Kowall, et al.). The presence of aggregations ofpA and neural atrophy within the same 
areas of the brain indicate that pA may be responsible for the neuronal degeneration found in patients 
with AD. Results ofnumerous studies have demonstrated toxic effects of pA and its fragments in areas 
of the brain involved in memory (Abe, Casamenti, Giovanelli, Scali, & Pepeu, 1994; Harkany, Lengyl 
et ai., 1995; Flood, Morley, & Roberts, 1994). 
One particular pathway of the brain implicated in learning and memory affected by pA is the 
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basal forebrain cholinergic system (for review see Guela & Mesulam, 1994) which includes the 
cholinergic projections of the nucleus basalis magnocellularis (nBM) to the cortex and amygdala, and 
the projections of the medial septal area (MSA) to the hippocampus and the parietal cortex. Injections 
ofpA peptide (1-42) into the nBM have been shown to reduce acetylcholinesterase (AChE) and 
choline acetyl transferase (ChAT) activity as well as significantly reduce the number of muscarinic 
ACh receptors (Harkany, Lengyl, et aI., 1995). Staining also revealed a degeneration of the neural 
fibers connecting the nBM to the frontal cortex, supporting the toxicity of pA within this cholinergic 
memory pathway (Harkany, Lengyl, et aI.). Other evidence supports the toxicity of pA within other 
areas of the basal forebrain cholinergic system. Injections of three different pA fragments into the 
MSA of separate groups of animals have been shown to produce a marked decrease in basal and K+­
evoked ACh release in the hippocampus 7 days following injections of 5nm of PA(12-28) and PA(25­
35), or 21 days following 3nm of PA(1-40) (Abe et aI., 1994). 
Collectively, these studies support the idea that pA targets cholinergic neurons, causing 
hypofunction of the cholinergic system. Approximately 90% of the cholinergic neurons in the brain are 
found within the basal forebrain cholinergic system, most specifically in the nBM and MSA. 
Aggregation of pA in these areas along with studies of the toxicity of this peptide and its fragments in 
these areas, suggest the hypothesis that pA targets these major cholinergic pathways, such as the nBM 
cortical projection and the septo-hippocampal pathway, which playa role in memory function(Abe et 
aI., 1994; Harkany, Lengyl, et aI., 1995). 
Further study has supported toxicity of pA to noradrenergic neurons (Emre, Geula, Ransil, & 
Mesulam, 1992). Intracerebral injections of pA(1-40), when compared to controls injected with the 
reverse amino acid sequence, revealed significant neurotoxic effects in the immediate vicinity of the 
injection site on both cholinergic and noradrenergic neurons to relatively the same extent (Emre et aI.). 
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Like acetylcholine, norepinephrine (NE) has also been shown 
to playa role in memory, especially in the neuronal projection from the pontine nucleus locus 
coeruleus (LC) to the hippocampus. This projection has been shown to be degenerated in patients with 
AD (Wang, Lui, Reddy, & Barnes, 1994). Administration ofpA into the hippocampus is followed by 
degeneration ofNE axons which project to the hippocampus (Wang et aI.). Two or three injections of 
pA (1-40) or pA (25-35), into the hippocampus once a week over three weeks resulted in loss in the 
hippocampus of neurons containing both glutamate (which is co-localized with NE in the LC) and 
tyrosine hydroxylase (the rate limiting enzyme in NE synthesis)(Wang et aI.). 
In contrast to neurotoxic effects of pA on cholinergic and noradrenergic systems within the 
brain, pA is not toxic to GABAergic neurons located within the basal forebrain cholinergic system 
(Harkany, Dejong, et aI., 1995). These GABAergic neurons within the basal forebrain cholinergic 
system are not involved in memory function (Harkany, Dejong, et aI.). Evidence from these studies 
assessing the differential toxicity of pA on cholinergic, noradrenergic and GABAergic pathways in the 
brain (Wang et aI., 1994; Harkany, Dejong et aI.; Harkany, Lengyl et aI., 1995) suggests that pA may 
be selectively neurotoxic within the neural pathways and transmitter systems involved in memory 
while not affecting other transmitter systems in the brain not involved in memory function. This 
evidence is consistent with the hypothesis that pA is the toxic agent responsible for the specific neural 
degeneration of regions and transmitter systems involved in memory functioning. 
While evidence supports the presence of neuropathology following injections of pA which 
corresponds to that observed in AD patients, conflicting data are reported in the literature on the 
development of behavioral memory deficits as a result of PA injections. Doman, D. Kang, 
McCampbell, and E.Kang (1993) reported that bilateral injections of either two doses of PA(25-35) or 
a subthreshold dose of ibotenic acid (IBO), an excitotoxin, into the hippocampus failed to produce a 
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significant effect on spatial learning in the rat, but identical injections of ~A(25-35) and IBO together 
resulted in a disruption in acquisition of spatialleaming when compared to controls (Doman et al.). 
While no behavioral learning and memory impairments were found following injections of ~A or IBO 
alone, the observed synergistic effects of these ~A injections with excitotoxins suggests that 
neuropathological damage may have been present, but not extensive enough to overcome neural 
compensation and produce observable behavioral deficits. This suggests that perhaps single injection 
of ~A may be responsible for the inconsistent behavioral impairments reported in the literature. A 
single injection may not produce lesions extensive enough to produce observable behavioral deficits. 
Recently, attempts have been made to produce more extensive ~A lesions by administering 
multiple injections or chronically infusing ~A over a prolonged period, in order to attain behavioral 
spatial learning deficits. Nitta, Itoh, Hasegawa, and Nabeshima (1994), found that infusion of ~A(1­
40) into a cerebral ventricle of a rat over 14 days using a mini-osmotic pump led to a subsequent 
behavioral spatial learning impairment on a water maze task. In another experiment, the behavioral 
effects of2 treatments of~A(25-35) injections bilaterally into the hippocampal areas CAI-3 were 
evaluated on a water maze task (Chen, Wright, & Barnes, 1994). It was reported that rats receiving 
multiple injections of ~A(25-35) displayed a spatial learning impairment, exhibiting significantly 
longer escape latencies and pathlengths to the platform than controls (Chen et al.). These studies 
suggest that multiple injections or chronic administration of ~A peptides may produce not only the 
specific neuropathological effects associated with Alzheimer's disease, but also the resulting 
behavioralleaming deficits. 
These techniques can be employed in order to determine the role of ~A toxicity on behavior 
following multiple injections or chronic administration into various regions of the brain that are known 
to degenerate in AD patients. In review, it has been previously reported that injections of ~A(25-35) 
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into the medial septal area (MSA) of rats produces a hypofunction of the cholinergic system with a 
decrease in ACh release in the hippocampus (Abe et aI., 1994). Doman, Tinkler, Litwiller, Fan, and 
Hanin (1996) used the technique ofmultiple injections to further investigate the neural pathway from 
the MSA to the hippocampus, referred to as the septo-hippocampal pathway. Injections of 5nm of 
~A(25-35) were given into three different depths of the MSA in male rats and spatial learning ability 
was then assessed using the Morris water maze and radial arm maze (Doman et al.). They report a mild 
behavioral memory impairment in these animals compared to controls receiving saline injections when 
they were tested on the radial-arm maze task (Doman et al.). 
It was the aim of this study to obtain additional data to test the hypothesis that 5nm injections 
of~A(25-35) into three different depths of the MSA leads to degeneration of the septo-hippocampal 
pathway resulting in spatialleaming and memory impairments. Establishing a causal link between 
~A, degeneration of specific areas such as the septo-hippocampal pathway, and memory impairments, 
would aid in the development of a useful animal model of the pathology ofAlzheimer's disease and 
perhaps in the elucidation of the role ~A plays in the etiology of Alzheimer's disease. 
Method 
Subjects 
Eleven 10 month old aged male Long-Evans rats from the Illinois Wesleyan University animal 
colony were used. These rats were matched to the age used in the previous investigation by Doman et 
al (1996). The rats were housed individually in a temperature controlled environment at 20 degrees 
Celsius on a 12: 12lightJdark cycle (lights on at 6:00 and off at 18:00). Food and water were available 
ad lib throughout the experiment except during radial-arm maze testing when rats were maintained at 
85% of their previous body weight. 
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Apparatus 
Behavioral testing of spatial learning ability was assessed using the Morris water maze 
(MWM) and the radial-arm maze (RAM). These spatial learning tasks require that rats learn and 
perform tasks requiring memory of the locations determined by spatial cues, memory of the rules of 
the maze, and memory of what they have already done and locations they have already been. The 
MWM consists ofa circular fiberglass pool (Advanced Composite Technologies) measuring 183 cm in 
diameter which was filled with water (26 0 C) and rendered opaque by the addition of a non-toxic white 
tempera paint. The maze is separated into four quadrants labeled NE, SE, SW, NW. The RAM consists 
of a central chamber from which eight arms, with removable plexiglass barriers, protrude at 45 0 angles 
from the adjacent arms on either side. During all testing the rat was introduced into the central 
chamber. Both mazes were located in individual observation rooms which are filled with salient visual 
cues which remained unchanged throughout the course of the experiment. All data were collected with 
the aid of a computerized tracking system. 
Emcedures 
Surgeries For all surgeries, animals were anaesthetized with a 100mglkg intra-peritoneal (IP) 
injection of a KetaminelXylazine cocktail, comprised of lOml of 100mg/ml Ketamine and 1.5ml of 
100mg/ml Xylazine. Animals received stereotaxically implanted 22-gauge stainless steel guide 
cannulas with inner stylets (to prevent occlusion). Cannulas were directed above the medial septal area 
(from bregma, AP=+0.8 mm, ML=O.O mm, DV= -5.2 mm) using the atlas ofPaxinos and Watson 
(1986) as a guide. The cannulas were secured with cranioplastic cement. 
IntracerebrallIijections Each rat received 3 injections of either PA(25-35) (n=5) or vehicle 
(n=6) into 3 different depths of the MSA. The vehicle for the PA(25-35) injections was a solution of 
35% Acetonitrile and 0.1 % Triflouroacetic acid in distilled water. Prior to injection all rats were 
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anesthetized with a 100mglkg KetaminelXylazine cocktail. Thirty-gauge injector cannulas were 
inserted into the chronically implanted guide cannula that protruded into the MSA. The injector 
cannulas were used to infuse 11.11 of PA(25-35) at a dose of 5nm/lll or vehicle at a depth of DV=-6.2 
mm. All injections were infused using a Stoelting micro infusion pump over the course of a half-hour 
and the injector was removed five minutes after the injection was complete in order to limit diffusion 
up the needle track. The animals were kept warm with the aid of a heating pad until they become self­
ambulating. Seven days following the first infusion, all rats were again anaesthetized and received a 
second infusion of PA(25-35) or vehicle which was administered identical to the first infusion only 
deeper into the MSA at a depth ofDV=-7.2. Seven days after the second infusion, all rats were 
anaesthetized again and received a third infusion of PA(25-35) or vehicle which was administered 
identically to the first infusion only deeper into the MSA at a depth ofDV=-8.2. Following the third 
infusion all cannulas were immediately plugged with bone wax. 
MorrisJ.Vm:eLMazeJesting Three days following their last infusion, all rats were tested on the 
MWM. Rats were tested four times per testing session. For each trial, the animal was placed at one of 
the four start locations (in the middle of the NE, SE, SW, or NW quadrant) such that each start location 
was used once each testing session. A random sequence of start locations was used on each day of 
testing. Each animal was allowed 90 seconds to find a submerged platform which was located 2 em 
below water level. If the animal failed to fmd the platform during the 90 second interval, it was gently 
guided to it and left on the platform for 10 seconds. After the animal had remained on the platform for 
10 seconds it was removed from the pool and ten seconds were allowed to lapse before the next trial 
began. After the four trials were completed, the rat was removed from the pool, dried and returned to 
its cage. Escape latency (the amount of time required to locate the platform in seconds), pathlength (in 
pixels), and swimspeed (in pixels/second) were recorded. Differences were expected between groups 
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on escape latency and pathlength, but not on swimspeed. 
On the first day of MWM testing, all rats were assessed using a non-cued task where the 
platform was not visible. The submerged platform was located and remained in the NW quadrant for 
all non-cued testing trials. Non-cued memory testing was performed once each day over the course of 
five consecutive days. 
Immediately following the completion of non-cued testing trials the task was changed 
to a reversal task. In this task the platform was moved from the NW quadrant to the SE quadrant in 
order to assess the ability of rats injected with PA(25-35) and vehicle to adapt to the change in 
conditions and learn the new location of the platform. This type of response perseveration 
characterized by a difficulty in changing and adapting strategies to a new task has been noted in 
patients afflicted with Alzheimer's disease. The presence ofperseverative behavior was assessed in 
this task, but not expected due to perseverative behavior being considered a result of frontal lobe 
damage. Reversal task testing was performed for two consecutive days immediately following the last 
day of noncued testing in the MWM. 
Immediately following the completion of reversal testing trials the task was changed to a 
pharmacological challenge task. In this task, the effects ofIP injections of the cholinergic muscarinic 
receptor blocker scopolamine was assessed by performance of a reversal task. This was assessed in 
order to determine if cholinergic dysfunction is present but not severe enough to result in behavioral 
impairment. If injections of PA(25-35) compromised the cholinergic system it would be expected that 
injections of scopolamine would further reduce cholinergic activity by blocking the receptors on the 
remaining cholinergic neurons, facilitating prior cholinergic deficits. Scopolamine injections would 
act to potentiate the effects of a prior cholinergic depletion in animals that had received PA(25-35) 
where animals with a normal cholinergic system would be able to compensate. This would lead to 
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more drastic behavioral impairment in animals who had a compensated cholinergic system as a result 
of PA(25-35) injections. 
Four days of a pharmacological challenge task was conducted immediately following the last 
day of reversal testing. All rats received IP injections of Scopolamine hydrobromide in physiological 
saline at a dose of .3mglkg on days 1 and 3 while no additional treatment was given on days 2 or 4 in 
order to assess recovery from the drug. All rats were tested 15 minutes after receiving injections. 
Before the scopolamine testing trials began the platform was moved from the SE quadrant to the SW 
quadrant. Scopolamine has a short half-life and no carryover effects of the drug are expected to 
interfere with testing on the days when the drug is not administered. 
Radial-ArmMazeJesting Following MWM testing, spatial learning ability was assessed 
using the radial-arm maze (RAM). The RAM not only tests memory of locations based on spatial 
cues, but also tests proactive and retroactive memory errors in a delayed non-matching to sample task. 
Following MWM testing, all rats were food deprived and maintained at 85% their previous body 
weight. Three days following the completion ofMWM testing and the initiation of food deprivation 
they were exposed to a 3-day adaptation phase using the RAM. During this phase, reinforcers 
(Cheerios) were liberally scattered on the RAM. The animals were placed on the center of the maze 
and allowed to explore for 5 minutes. Following the adaptation trial on the third day the last phase of 
adaptation was completed, all animals were once again introduced to the maze that same day for five 
minutes with only the ends ofeach arm baited as they were in further testing. 
Following the adaptation phase, each animal was tested once each day for nine days. Animals 
were introduced to the RAM twice during each testing session. In the first trial, or pre-delay trial, four 
arms were blocked off and the remaining four arms were baited with the reinforcer. Each rat was 
placed in the center of the RAM and allowed five minutes to visit the four open arms. All rats were re­
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introduced to the RAM after an hour delay, all eight arms were open, and the four arms that were 
previously blocked were baited in this delay condition. The configuration of the blocked arms were 
never repeated and were changed on a daily basis. This type of task is often referred to as a "delayed­
non-matching to sample task" or DNMTS. During the delay trials the following behavioral parameters 
were recorded: 1) retroactive memory errors, entries into previously baited arms, and 2) proactive 
memory errors, number of reentries into arms previously visited in this trial. These types of memory 
errors display more immediate and post-delay memory loss (proactive and retroactive, respectively) 
that may parallel short and longer term memory deficits noted in patients with Alzheimer's disease 
(Berg & Morris, 1994). 
Histological Verification One week following the last day of behavioral testing, all animals 
were sacrificed, perfused, and the brains removed. The brain of one animal from each group was 
sectioned and stained with Cresyl Violet in order to verify the location of the cannula placement. 
Further histological analysis will examine the medial septal area of all remaining animals receiving 
injections of PA(25-35) and a control animal from each group, sectioning and staining with a Congo 
red histological stain in order to assess the level of aggregated pA plaques in the MSA. 
Results 
Morris Water maze 
Rats receiving injections of PA(25-35) performed no different than rats receiving injections of 
vehicle on all MWM tasks. For all tests the Bonferroni index was used, utilizing a more conservative 
alpha level of .001 in order to take into account the large number of unweighted means analyses of 
variance which were performed. In the non-cued task no significant effects of injection were found on 
escape latency [E (1,54) = .0026, P > .9](see fig. 1), pathlength [E (1,54) =.11 p> .7](see fig. 2), or 
swimspeed [E(1, 54) = .15, P > .7](see fig. 3). These results along with a non-significant day-by­
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injection condition interactions for escape latency [E (4,54) = 1.33, P > .2], pathlength [E(4, 54) = .92, 
p> .4], and swimspeed [F(4,54) = 1.38, P > .2] indicate that multiple injections of J3A(25-35) into the 
MSA had no significant effects on water-maze performance in the non-cued trials when compared to 
controls. A main effect of days was noted on escape latency [F (4,54) = 14.13, P < .0001], pathlength 
[E (4, 54) = 7.67 P < .0001], and swimspeed [E(4, 54) = 16.88, p < .0001] revealing that both groups 
learned the task and significantly improved over days. 
Similarly, in the reversal trials, no significant effects of injection condition were found on 
escape latency [E (1,21) = .92, P < .3](see fig. 4), pathlength [E (1,21) = .39, P < .5](see fig. 5), or 
swimspeed [E(1,21) = 1.00, p >.3](see fig. 6). A marginal effect (but not significant at an alpha level 
of .001) of injection condition was noted on time spent in quadrant the platform was previously located 
with control animals spending more time in the quadrant than animals injected with J3A(25-35) [E(1, 
21) = 6.7, p < .03](see fig. 7). No significant main effect ofdays was noted for all parameters 
signifying that both groups failed to significantly improve on the reversal task from the first day to the 
second day oftrials. No day-by-injection condition interactions were found for escape latency [E (1, 
21) = .30, p> .5], pathlength [F (1,21) = 0.45, p> .5], swimspeeq [F (1,21) = 0.08, p> .7], or time 
spent in previous quadrant [E(1, 21) = .31, P > .5]. Collectively, this data indicates that multiple 
injections of J3A(25-35) into the MSA failed to have an appreciable effect on water maze performance 
in the reversal trials when compared to controls. 
On days where the cholinergic antagonist scopolamine was administered in the 
pharmacological challenge task, no significant main-effects were noted between animals receiving 
injections of J3A(25-35) and controls. No significant effects of injection condition were found on 
escape latency [E (1,21) = .11, P >.7](see fig. 8), pathlength [E (1,21) = .17, P > .6](see fig. 9), or 
swimspeed [F(1,21) = .93, p >.3](see fig. 10). While a mild effect ofdays was observed on escape 
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latency [E (1, 21) = .11.69, P < .008](see fig. 8) and pathlength [E (1,21) = .012, P > .02](see fig. 9), 
denoting improvement over the course of the task, this was not sufficient to display a significant effect 
of days at a conservative alpha level of .001. As in both previous water maze tasks, no significant day­
by-injection condition interactions were observed for escape latency [E (1,21) = .075, P > .7], 
pathlength [E (1, 21) = 0.85, P > .8], swimspeed [E (1,21) = .39, p> .5]. In summary, no significant 
effects of injections of PA(25-35) into the MSA were observed on spatial Ieaming as assessed on the 
Morris water maze. 
Radial-A~e 
The data was averaged into blocks of three days for statistical analyses. Data analysis began 
on day six of the RAM testing (by day six most animals had begun to consistently perform the task) 
For all tests a more conservative alpha level of .001, in accordance with the Bonferroni index, was 
used in order to take into account the large number of ANOVAs that were performed within this study. 
An unweighted means analysis of variance (mixed design) with blocks as the repeated measure, and 
injection condition as the between measure, on retroactive memory errors revealed no significant main 
effect of injection condition [E (1,77) = 2.86, P > .1 ](see fig. 11) or block-by-injection condition 
interaction [F (1, 77) = .97, P > .3]. Similar statistical analysis on proactive memory errors failed to 
find a significant effect of injection condition [F (1,77) = .88, p> .3](see fig. 12) or block-by-injection 
condition interaction [E (1, 77) = 1.6, P >.2]. A moderate effect of blocks was displayed for both 
retroactive memory errors [E (2,77) = 5.33, P < .008] and proactive memory errors [E (2,77) = 4.24, P 
< .02] displaying improvement of all animals over blocks, but both measures failed to be statistically 
significant at a more conservative alpha level of .00 I. These results reveal that multiple injections of 
PA(25-35) into the medial septal area had no significant effects on the radial-arm maze task when 
compared to controls. 
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NellfOChemical Analys~d Histochemical Verification 
Analysis of brain sections stained with Cresyl Violet revealed that the location of the cannula 
placements examined were directed at the Medial Septal area as intended in the surgical procedure. 
Further histological analysis ofthe brains of these animals will be done to determine the effects of 
injection condition on the brain areas of interest. 
Discussion 
The present study displays that three injections of PA(25-35) into three different depths of the 
medial septal area of the male rat fails to induce behavioral spatial learning deficits as assessed on the 
Morris water maze and radial-arm maze. In contrast to the results of this study, many recent studies on 
the behavioral effects of different pA fragments following multiple injections (Chen et aI., 1996; 
Doman et aI., 1996) or chronic administration (Nitta et aI., 1994) of these peptides into various 
regions of the brain associated with learning and memory function have found spatial learning 
impairments. A study by Doman et aI. (1996) assessing the effects ofmultiple injections of PA(25-35) 
into the MSA employed identical surgical, injection, and behavioral testing procedures and found a 
marginal effect on spatial learning accompanied by a disruption of the cholinergic septo-hippocampal 
pathway which was noted 60 days following the last injection. The present study failed to replicate 
these findings and provides contrary evidence as to the behavioral effects ofmultiple injections of 
PA(25-35) into the MSA. 
Curiously, not only did this study fail to find any significant effects of injection PA(25-35) on 
spatial learning, but the only effect on a trend towards significance was on time spent in the previous 
quadrant in the reversal MWM task. In this task, control animals spent more time in the quadrant the 
platform was previously located in than did animals receiving injections of PA(25-35). This displays a 
greater difficulty of control animals to adapt their search strategy. This trend was opposite of what 
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was expected given previous evidence. This effect could be due to a stronger memory of the previous 
location in control animals in comparison to those injected with PA(25-35). This is supported by 
similar escape latencies and pathlengths displayed in PA(25-35) animals on the last day of non-cued 
trials and in the reversal trials while the escape latencies and pathlengths of control animals 
dramatically increased the first day following the change in task. This difficulty of the control animals 
may have been due to a stronger knowledge of the previous non-cued task while weaker memory of 
the task in PA(25-35) animals may have caused less of a problem for these animals in adapting to a 
new task. Perseveration in PA(25-35) animals, denoted by a more time spent in quadrant the platform 
was previously located in, would not be expected given no frontal lobe damage, which is believed to 
be responsible for perseverative behavior, should be present in these animals. The combined results of 
this study, in contrast to previous fmdings, do not support that multiple injections of PA(25-35) into 
the MSA produce spatial learning deficits in the male rat. 
One possible explanation of the lack of spatial learning deficits following these injections of 
PA(25-35) is that no cholinergic depletion was present and no degeneration of the septo-hippocampal 
pathway occurred as a result of these injections. Further histological examinations will aid in 
revealing if this is indeed the explanation of the observed results of this study, or whether other 
implications are warranted from these results. In future study, the histology of these animals will be 
examined in order to determine if aggregated amyloid plaques or cavitation of brain tissue is present. 
Cavitation of brain tissue is a primary indicator of cell death and observed cavitation would support the 
presence of a neurochemical depletion within the brain areas as a result of pA injections. The 
presence or absence of neuritic plaques, comprised of aggregated PA(25-35), in the MSA which are 
thought to be responsible for disruption of the septo-hippocampal pathway may also aid in determining 
whether a neurochemical depletion may be present. An additional experiment, which is currently in 
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progress, again replicated these surgical procedures of this study will assess the neurochemical effects 
of three identical injections of PA(25-35) into the MSA at a shorter interval of three weeks following 
the final injection. These future studies will aid in establishing whether this methodology produces 
consistent and reliable cholinergic depletions as that previously reported (Dornan et aI., 1996). 
One possible explanation for the lack of any marked effect on spatial learning, even despite 
reduction of cholinergic input to the hippocampus could be the result of postsynaptic up-regulation of 
hippocampal muscarinic receptors. This hypothesis was tested using a pharmacological challenge 
task. No differences, however, were observed on escape latencies, pathlengths or swimspeeds between 
the two groups following J.P. injections of the muscarinic receptor blocker scopolamine. This supports 
the hypothesis that a profound cholinergic depletion was not present in the animals used in this study. 
The greatest limitation of this study is that it does not directly observe neurochemical levels in 
the MSA. Without this data, it will remain unknown if the lack of behavioral impairment was the 
result of a failure to produce cholinergic degeneration of the septo-hippocampal pathway or if the 
previously reported marginal impairments on the RAM following identical procedures (Dornan et aI., 
1996) was due to random differences in the animals tested. Histological data over the course of the 
experiment would also aid in developing a fuller understanding of the role of PA(25-35) in this 
experiment. There are no data to suggest whether previously reported disruptive effects of the PA(25­
35) injections were progressive over the course of the experiment, whether compensation and recovery 
occurs, or if the effects will remain fairly constant over the course of the study. This data would not 
only aid in the elucidation of the role of PA(25-35), but would also clarifying whether the pA 
administration methodology used in this experiment produces a cholinergic depletion. It is for this 
reason that a study is in progress in order to determine the histological and neurochemical effects of 
the identical surgical procedures after a three week period of time. One additional limitation of the 
-Effects of Multiple Injections of pA (25-35) 18 
study is the lack of a control group not receiving any surgical procedures in order to assess 
performance of a normal rat on these spatial learning tasks and allow for comparison. 
Despite the lack of significant results in this study, it has raised questions concerning the 
conclusions of Doman et al. (1996) and the behavioral effects of PA(25-35) following multiple 
injections into the MSA. These findings wi11lead to further experimentation in order to resolve the 
conflicting evidence which has risen from this study. This further experimentation will aid in the 
development of an animal model of Alzheimer's disease and perhaps lead to the elucidation of the 
exact role pA plays in the etiology of Alzheimer's disease. 
•
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Figure Captions 
Figure l Mean escape latencies to a hidden platform in rats following multiple injections of pA (25­
35) or vehicle into the MSA were measured on a non-cued Morris water maze task. Each rat 
received four tests per day for 5 consecutive days. Vertical lines represent +s.e.m. See text for 
details. 
Eigure2. Mean pathlengths to find the hidden platform in rats following multiple injections of pA 
(25-35) or vehicle into the MSA were measured on a non-cued Morris water maze task. Each rat 
received four tests per day for 5 consecutive days. Vertical lines represent +s.e.m. See text for 
details. 
Figure3. Mean swimspeeds onto a hidden platform in rats following multiple injections of pA (25­
35) or vehicle into the MSA were measured on a non-cued Morris water maze task. Each rat 
received four tests per day for 5 consecutive days. Vertical lines represent +s.e.m. See text for 
details. 
FigureA. Mean escape latencies to a hidden platform in rats following multiple injections of pA (25­
35) or vehicle into the MSA were measured on a reversal Morris water maze task. Each rat received 
four tests per day for 2 consecutive days. Vertica1lines represent +s.e.m. See text for details. 
Figure 5~ Mean pathlengths to find the hidden platform in rats following multiple injections of pA 
(25-35) or vehicle into the MSA were measured on a reversal Morris water maze task. Each rat 
received four tests per day for 2 consecutive days. Vertical lines represent +s.e.m. See text for 
details. 
EigureJ5. Mean swimspeeds onto a hidden platform in rats following multiple injections of pA (25­
35) or vehicle into the MSA were measured on a reversal Morris water maze task. Each rat received 
four tests per day for 2 consecutive days. Vertica1lines represent +s.e.m. See text for details. 
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Eigu~. Mean times spent in the quadrant the hidden platform was previously located following 
multiple injections of pA (25-35) or vehicle into the MSA of rats were measured on a reversal 
Morris water maze task. Each rat received four tests per day for 2 consecutive days. Vertical lines 
represent +s.e.m. See text for details. 
EigIll"e 8~ Mean escape latencies to a hidden platform following LP. injections of scopolamine as 
measured on a reversal Morris water maze task. Each rat received four tests per day on 2 days with 
a day of non-drug testing following each day of drug testing. Vertical lines represent +s.e.m. See 
text for details. 
Figur~9. Mean pathlengths to find the hidden platform following 1.P. injections of scopolamine as 
measured on a reversal Morris water maze task. Each rat received four tests per day on 2 days with 
a day of non-drug testing following each day of drug testing. Vertical lines represent +s.e.m. See 
text for details. 
EiguruQ. Mean swimspeeds onto a hidden platform following LP. injections of scopolamine as 
measured on a reversal Morris water maze task. Each rat received four tests per day on 2 days with 
a day of non-drug testing following each day of drug testing. Vertical lines represent +s.e.m. See 
text for details. 
Eigure~L Effects of multiple injections of pA (25-35) into the MSA on the mean number of 
retroactive memory errors on a standard RAM task with a 1 hour delay. Retroactive memory errors 
are defined as entries into unbaited arms that were baited and visited during the pre-delay session of 
the trial. Vertical lines represent +s.e.m. See text for details. 
Figu~lL Effects of multiple injections of pA (25-35) into the MSA on the mean number of 
proactive memory errors on a standard RAM task with a I hour delay. Proactive memory errors are 
defined as re-entries into any arm during the post delay session of the trial. Vertical lines represent 
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+S.e.ID. See text for details. 
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